Lunai Bioworks Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2025-12-31; filed 2026-02-17.
0001731122-26-000253
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresCurrent report: 10-Q
Period ended 2026-03-31; filed 2026-05-15.
0001731122-26-000749
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 8 previous paragraphs and 9 current paragraphs.
7 unchanged; 0 reworded; 2 added; 1 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (2)
Current report
On March 24, 2026, the Company entered into separate Debt Exchange Agreements with three holders of its secured promissory notes (the “Holders”), pursuant to which the Company issued an aggregate of 3,909,293 shares of common stock and warrants to purchase up to 1,433,621 shares of common stock at an exercise price of $0.21 per share, in exchange for the cancellation of $828,770 of outstanding principal and accrued interest under the secured promissory notes held by the Holders. The shares of common stock and warrants (and the shares of common stock issuable upon exercise of the warrants) were issued in reliance upon the exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 3(a)(9) thereof (relating to exchanges with existing security holders for no consideration paid for soliciting the exchange) and Section 4(a)(2) thereof (relating to transactions not involving a public offering). The Company filed a Current Report on Form 8-K disclosing these transactions on March 30, 2026.
Current report
(c)Issuer Purchases of Equity Securities. None. The Company did not repurchase any shares of its common stock or other equity securities during the three months ended March 31, 2026.